1. Home
  2. LINC vs DRUG Comparison

LINC vs DRUG Comparison

Compare LINC & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lincoln Educational Services Corporation

LINC

Lincoln Educational Services Corporation

HOLD

Current Price

$36.27

Market Cap

732.0M

Sector

Real Estate

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$81.04

Market Cap

856.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LINC
DRUG
Founded
1946
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Pharmaceuticals and Biotechnology
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
732.0M
856.4M
IPO Year
2005
2020

Fundamental Metrics

Financial Performance
Metric
LINC
DRUG
Price
$36.27
$81.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
5
Target Price
$37.50
$114.00
AVG Volume (30 Days)
472.4K
90.3K
Earning Date
05-26-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.23
N/A
Revenue
$261,853,000.00
N/A
Revenue This Year
$9.55
N/A
Revenue Next Year
$8.13
N/A
P/E Ratio
$150.39
N/A
Revenue Growth
32.98
N/A
52 Week Low
$14.10
$23.18
52 Week High
$36.42
$123.75

Technical Indicators

Market Signals
Indicator
LINC
DRUG
Relative Strength Index (RSI) 77.68 50.24
Support Level $21.46 $73.97
Resistance Level N/A $97.75
Average True Range (ATR) 1.86 5.76
MACD 0.72 0.72
Stochastic Oscillator 98.17 53.97

Price Performance

Historical Comparison
LINC
DRUG

About LINC Lincoln Educational Services Corporation

Lincoln Educational Services Corp provides diversified career-oriented post-secondary education to high school graduates and working adults. The company offers programs in automotive technology, skilled trades, healthcare services, hospitality services, and business and information technology. Its reportable segments include; Campus Operations, and Transitional. The majority of the revenue is generated from the Campus Operations segment which includes all campuses that are continuing in operation and contribute to the Company's core operations and performance.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: